Miguel
Cervero Jiménez
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (12)
2023
-
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study
Journal of Clinical Medicine, Vol. 12, Núm. 23
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2018
2015
-
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus
Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958
2014
-
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2011
-
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus
Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092